stavudine: eu approval for first-line therapy in hiv

22 DRUG REACTIONS MARKET NEWS Stavudine: EU approval for first-line therapy in HIV Bristol-Myers Squibb's stavudine [d4T, 'Zerit'] has been approved by the European Union (EU) for use as fIrst-line therapy, in combination with other antivirals, in adults and children with mv infection. Clinical trials have shown that stavudine combination therapy in adults and children with IllY infection effectively reduces viral load (often to undetectable levels) and increases CD4+ cell counts. Stavudine has been available in the EU since 1996 for use in patients with IllY infection for whom zidovudine is not, or is no longer, appropriate, and is also available in several other countries worldwide. Bristol-Myers Squibb Company. Zerit (R) (stavudine) approved for first-line treatment of mv in Europe; indication includes adults and children. Media Release: [1 page], 25 Aug 1997 100>51266 Inpharma- 30 Aug 1997 No. 1102 1173-8324197/1102-00022/$01.00° Adls International LimHed 1997. All rights raserved

Post on 13-Dec-2016

214 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: Stavudine: EU approval for first-line therapy in HIV

22 DRUG REACTIONS

MARKET NEWS Stavudine: EU approval for first-line therapy in HIV

Bristol-Myers Squibb's stavudine [d4T, 'Zerit'] has been approved by the European Union (EU) for use as fIrst-line therapy, in combination with other antivirals, in adults and children with mv infection.

Clinical trials have shown that stavudine combination therapy in adults and children with IllY infection effectively reduces viral load (often to undetectable levels) and increases CD4+ cell counts.

Stavudine has been available in the EU since 1996 for use in patients with IllY infection for whom zidovudine is not, or is no longer, appropriate, and is also available in several other countries worldwide. Bristol-Myers Squibb Company. Zerit (R) (stavudine) approved for first-line treatment of mv in Europe; indication includes adults and children. Media Release: [1 page], 25 Aug 1997 100>51266

Inpharma- 30 Aug 1997 No. 1102 1173-8324197/1102-00022/$01.00° Adls International LimHed 1997. All rights raserved

HBV and HIV HIV and HBV

Bio-Nano-Chip Technologies for HIV Management and Prevention” · prevention, management and treatment. 2) Define accelerated approval pathways both in US and resource scarce settings

Toxicity of stavudine- and nevirapine-containing antiretroviral treatment regimens: incidence and risk factors after 3 years in a large cohort in Rwanda

STAVUDINE- stavudine for solution Cipla Ltd....Cipla Ltd.-----HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STAVUDINE FOR

COMPARATIVE STUDY OF STAVUDINE …web.usm.my/mjps/mjps08022010/mjps08022010_4.pdfCOMPARATIVE STUDY OF STAVUDINE MICROSPHERES PREPARED USING ETHYLCELLULOSE ALONE AND IN COMBINATION

HIV Evidence Infographic – HIV Testing & Counseling

· # 1 1--1CV HCV . T-bil HIV GPT,_ ALPx (BIM-5) OffiHIV L < &fiö *HIV 9 # 1 HIV HIV ä HIV HIV a . HBsfiJH ( ) ( ) HCVffi# ( ) ( ) (4)ffifZ a 5) * HIV fif$. 2 HI HIV HIV 1000/0,

HIV, HBV, HCV Virology · The HIV virology timeline HIV-1 genome sequenced HIV replicates at high levels throughout the infection HIV replication drives immune compromise Plasma HIV

HIV Diagnostics and Acute HIV - UAB

Stavudine Loaded Biodegradable Polymeric Microspheres as a ...oaji.net/articles/2014/364-1402081612.pdf · Injectable biodegradable polymeric microspheres of Stavudine were prepared

HIV-1/HIV-2 PLUS O